Under Rs 2650 Stocks to Buy in November 2026: 5 Names on the Watchlist

The under Rs 2650 stocks to buy in November 2026 start with five listed names: Affle 3i, Cholamandalam Investment and Finance, Dr Lal PathLabs, Happy Forgings and Ipca Laboratories. Stocks under Rs 2,650 include a mobile advertising platform, a vehicle finance company, a forgings maker, a pharma company and a diagnostics chain, priced from about Rs 1,626 to Rs 2,017.

This article ranks none of them as a sure thing. It lays out the numbers each company has reported, how the shares are priced today and what an investor should check before adding any of these under Rs 2650 stocks to buy to a portfolio. All prices are NSE closing prices of 9 November 2026, and financials come from company filings.

Click Here – Get Free Investment Predictions

Which Are the Best Under Rs 2650 Stocks to Buy in November 2026?

The best under Rs 2650 stocks to buy in November 2026 for a watchlist are Affle 3i, Cholamandalam Investment and Finance, Dr Lal PathLabs, Happy Forgings and Ipca Laboratories. They were picked because each has complete reported financials, profit in the latest quarter and an NSE listing. The table puts their market data side by side.

Company	CMP (Rs)	Market Cap	P/E	ROE	Dividend Yield
Affle 3i	1,626	Rs 20,293 crore	42.48	12.45%	0.00%
Cholamandalam Investment and Finance	1,791	Rs 1,37,140 crore	22.04	18.02%	0.12%
Dr Lal PathLabs	2,016	Rs 32,115 crore	58.78	20.13%	1.07%
Happy Forgings	1,802	Rs 16,943 crore	51.75	14.17%	0.22%
Ipca Laboratories	1,960	Rs 48,860 crore	35.53	14.15%	0.31%

On valuation, Dr Lal PathLabs, Happy Forgings and Ipca Laboratories sit close to it; Affle 3i and Cholamandalam Investment and Finance carry a premium. Valuation is the first filter for any under Rs 2650 stocks to buy list, and it is covered again in the risk section.

Why These Under Rs 2650 Stocks to Buy Are in Focus

A higher share price does not mean a stock is expensive, because value depends on earnings and the number of shares. The list covers a mobile advertising platform, a large vehicle finance company, a maker of forged components, a maker of pharma formulations and active ingredients and a diagnostics chain, all of which closed below Rs 2,650 on the NSE on 9 November. Investors searching for the best stocks under Rs 2,650 in India should check earnings, valuation and debt.

Affle 3i: The AI-Driven Ad Platform Among Under Rs 2650 Stocks to Buy

Affle 3i is a consumer-intelligence and mobile advertising platform that uses data and AI to drive app installs and engagement. At Rs 1,626, the stock has a market capitalisation of Rs 20,293 crore and trades at 42.48 times earnings, while the industry P/E is 17.58.

Reported numbers show FY26 revenue of Rs 2,788 crore, up 18.1% year on year, with net profit at Rs 455 crore, up 19.1%. The June 2026 quarter added revenue of Rs 772 crore (up 21.1%) and net profit of Rs 128 crore (up 21.7%).

Return on equity is 12.45%, debt-to-equity is 0.00, and the dividend yield is negligible. Promoters hold 55.42%, foreign institutions 14.36% and domestic institutions 18.88% as of October 2026. Domestic institutional holding has risen from 16.36% to 18.88% over the last year.

Cholamandalam Investment and Finance: The Vehicle Finance Specialist Among Under Rs 2650 Stocks to Buy

Cholamandalam Investment and Finance is a vehicle finance, home loan and small business lender in the Murugappa Group. Its market capitalisation is Rs 1,37,140 crore, the share price is Rs 1,791 and the P/E of 22.04 compares with an industry P/E of 16.15.

Over FY26, net profit rose 22.7% to Rs 5,229 crore on revenue of Rs 31,539 crore, which was up 20.6%. The latest quarter, the September 2026 quarter, brought revenue of Rs 9,395 crore, up 23.4% year on year, and net profit of Rs 1,630 crore, up 40.6%.

Return on equity is 18.02%, and the dividend yield is 0.12%. Promoters hold 48.93%, foreign institutions 24.87% and domestic institutions 20.38% as of September 2026. Domestic institutional holding has risen from 17.27% to 20.38% over the last year.

Check Under Rs 2650 Stocks Live on the Univest Screener

Dr Lal PathLabs: The Diagnostics Leader Among Under Rs 2650 Stocks to Buy

Dr Lal PathLabs is one of India's largest diagnostic chains, with a national network of labs and collection centres. The stock trades at Rs 2,016 with a market capitalisation of Rs 32,115 crore and a P/E of 58.78, against an industry P/E of 61.50.

FY26 revenue rose 12.1% to Rs 2,864 crore and net profit rose 3.6% to Rs 510 crore. In the June 2026 quarter, revenue grew 18.9% year on year to Rs 830 crore, while net profit grew 27.2% to Rs 170 crore.

Return on equity is 20.13%, debt-to-equity is 0.08, and the dividend yield is 1.07%. Promoters hold 52.93%, foreign institutions 18.73% and domestic institutions 21.58% as of September 2026. Domestic institutional holding has risen from 18.49% to 21.58% over the last year.

Happy Forgings: The Precision Forging Specialist Among Under Rs 2650 Stocks to Buy

Happy Forgings is a maker of precision forged and machined components for auto, industrial and renewable customers. At Rs 1,802, the stock has a market capitalisation of Rs 16,943 crore and trades at 51.75 times earnings, while the industry P/E is 48.76.

Reported numbers show FY26 revenue of Rs 1,577 crore, up 9.0% year on year, with net profit at Rs 302 crore, up 12.8%. The June 2026 quarter added revenue of Rs 460 crore (up 26.5%) and net profit of Rs 91.5 crore (up 39.2%).

Return on equity is 14.17%, debt-to-equity is 0.15, and the dividend yield is 0.22%. Promoters hold 78.44%, foreign institutions 2.37% and domestic institutions 14.93% as of September 2026.

Ipca Laboratories: The Formulations and API Name Among Under Rs 2650 Stocks to Buy

Ipca Laboratories is a pharma company making formulations and active ingredients, known for anti-malarial and pain-management products. Its market capitalisation is Rs 48,860 crore, the share price is Rs 1,960 and the P/E of 35.53 compares with an industry P/E of 37.65.

Over FY26, net profit rose 51.3% to Rs 1,191 crore on revenue of Rs 9,821 crore, which was up 8.7%. The latest quarter, the June 2026 quarter, brought revenue of Rs 2,813 crore, up 20.2% year on year, and net profit of Rs 423 crore, up 80.4%.

Return on equity is 14.15%, debt-to-equity is 0.10, and the dividend yield is 0.31%. Promoters hold 44.72%, foreign institutions 11.53% and domestic institutions 36.59% as of September 2026. Foreign institutional holding has risen from 10.43% to 11.53% over the last year.

Download the Univest iOS App or Univest Android App to track these under Rs 2650 stocks live and get daily stock recommendations.

Growth Snapshot: Latest Full Year and Latest Quarter

The table compares year-on-year growth in revenue and net profit for all five under Rs 2650 stocks, using filed results.

Company	Full-Year Revenue Growth	Full-Year Profit Growth	Latest Quarter	Quarter Revenue Growth	Quarter Profit Growth
Affle 3i	18.1%	19.1%	Jun 2026	21.1%	21.7%
Cholamandalam Investment and Finance	20.6%	22.7%	Sep 2026	23.4%	40.6%
Dr Lal PathLabs	12.1%	3.6%	Jun 2026	18.9%	27.2%
Happy Forgings	9.0%	12.8%	Jun 2026	26.5%	39.2%
Ipca Laboratories	8.7%	51.3%	Jun 2026	20.2%	80.4%

Factors That Move Under Rs 2650 Stocks to Buy

Four factors tend to drive under Rs 2650 stocks, and each one is worth checking before a purchase.

• Earnings growth: Profit should be rising.
• Sector mix: Advertising, finance, forgings, pharma and diagnostics differ.
• Dividends: Dr Lal PathLabs yields about 1.1%.
• Valuation: P/E runs from about 22 to 59.

Risks to Keep in Mind Before Buying Under Rs 2650 Stocks

The first risk is that a higher share price says little about value, so earnings and valuation matter more. The second is that Cholamandalam Investment and Finance carries the highest borrowings of the five as a lender, while Dr Lal PathLabs trades at a P/E near 59. Check results every quarter.

On the numbers, Dr Lal PathLabs trades at the highest P/E on this list at 58.78, so its earnings need to keep growing to support the price. Under Rs 2650 stocks to buy can still fall when markets turn weak, and a staggered entry has historically suited investors better than a lump-sum purchase.

How to Choose Under Rs 2650 Stocks to Buy

• Look at earnings: Price alone is not a signal.
• Check P/E: Cholamandalam Investment and Finance trades lowest.
• Read ROE: Dr Lal PathLabs leads.
• Diversify: Spread across the five sectors.

How to Invest in Under Rs 2650 Stocks

1. Shortlist two or three companies from this list that match your risk appetite.
2. Open the Univest Screener and compare P/E, ROE and debt for each stock.
3. Check the latest quarterly results and shareholding pattern on NSE or BSE.
4. Decide an amount you can hold for three to five years and split it into two or three purchases.
5. Review the holding after every quarterly result instead of reacting to daily price moves.

Conclusion

Cholamandalam Investment and Finance offers the lowest P/E on this list at 22.04, Dr Lal PathLabs has the highest return on equity at 20.13%, and Ipca Laboratories posted the fastest net profit growth in its latest full year at 51.3%. Among the best under Rs 2650 stocks in India, these five give investors a spread of size, valuation and growth, so the right pick depends on risk appetite and holding period. Spread the entry, keep position sizes sensible and consult a SEBI-registered advisor before investing in any of these under Rs 2650 stocks to buy.

Frequently Asked Questions on Under Rs 2650 Stocks to Buy

Which are the best under Rs 2650 stocks to buy in November 2026?

Ans. The five under Rs 2650 stocks on the November 2026 watchlist are Affle 3i, Cholamandalam Investment and Finance, Dr Lal PathLabs, Happy Forgings and Ipca Laboratories. Cholamandalam Investment and Finance has the lowest P/E at 22.04, Dr Lal PathLabs has the highest ROE at 20.13%, and Ipca Laboratories grew net profit 51.3% in its latest full year. This is educational content, not investment advice, so please consult a SEBI-registered advisor.

Is Cholamandalam Investment and Finance a good stock to buy from this Under Rs 2650 list?

Ans. Cholamandalam Investment and Finance is the largest company on this list with a market capitalisation of Rs 1,37,140 crore and a P/E of 22.04 against an industry P/E of 16.15. Its FY26 revenue rose 20.6% and net profit rose 22.7%, with return on equity at 18.02%. Whether it suits you depends on your risk appetite and holding period, so please consult a SEBI-registered advisor before investing.

Are these under Rs 2650 stocks expensive right now?

Ans. Valuations vary across the group. Affle 3i trades at a P/E of 42.48, Cholamandalam Investment and Finance trades at a P/E of 22.04, Dr Lal PathLabs trades at a P/E of 58.78, Happy Forgings trades at a P/E of 51.75, Ipca Laboratories trades at a P/E of 35.53, against industry multiples ranging from 16.15 to 61.50. Higher multiples reflect faster growth but also leave less room for earnings misses, so entry price deserves attention.

Which of these under Rs 2650 stocks pay a dividend?

Ans. Dividend yields on this list are Cholamandalam Investment and Finance 0.12%, Dr Lal PathLabs 1.07%, Happy Forgings 0.22%, Ipca Laboratories 0.31%. Yields are modest across the group, so most investors look at these stocks for growth in earnings rather than for income, and payouts can change with company profits.

Which stock on this list has the highest return on equity?

Ans. Dr Lal PathLabs has the highest ROE on this list at 20.13%, followed by Cholamandalam Investment and Finance at 18.02% and Happy Forgings at 14.17%. A higher ROE shows a company earns more profit on shareholder capital, but it should be read alongside valuation and debt.

What are the risks of investing in under Rs 2650 stocks?

Ans. The main risks are price levels that say little about value, funding costs at the lender and a wide spread in valuations. On this list, Dr Lal PathLabs trades at the highest P/E of 58.78, which leaves less room for earnings disappointments. Staggered buying and a long holding period can help manage these risks.

How can I invest in under Rs 2650 stocks in India?

Ans. You can buy these stocks directly on NSE or BSE through a demat account, and compare them first on the Univest Screener using P/E, ROE and debt. Many investors split the amount across two or three purchases and review the holding after each quarterly result. Sector-themed mutual funds and ETFs are another route for investors who prefer diversification.